Japan’s biggest drugmaker spent big in the past year to replenish its pipeline to make up for the loss of exclusivity on big sellers and give it time to develop some 40 treatments in the clinical stage., Japan’s biggest drugmaker spent big in the past year to replenish its pipeline to make up for the loss of exclusivity on big sellers and give it time to develop some 40 treatments in the clinical stage., , Read More

AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way